Texas

Texas

2405 Registered Patient Population

0.01% of Total Population Represented by Patients

0 Total Medical Retail Locations Currently in Operation

N/A Ratio of Patients to Retail Location

CBD treatment is legal in Texas. Patients with severe epilepsy may seek a doctor’s recommendation for cannabis oil with no more than 0.5 percent THC. The state has authorized dispensing organizations to cultivate, process, and distribute this medicine.

Patient Rights and Civil Protection	38/100
Arrest Protection 20/40 Affirmative Defense 9/15 Parental Rights Protections 0/10 DUI Protections 0/5 Employment Protections 0/5 Explicit Privacy Standards 4/7 Housing Protections 5/5 Does Not Create New Criminal Penalties for Patients 0/5 Organ Transplants 0/5 Reciprocity 0/3
Access to Medicine	29/100
Allows Distribution Programs 9/40 – Allows Access to Dried Flowers 0/15 – Allows Delivery 3/5 – No Sales Tax or Reasonable Sales Tax 0/5 – Allows for a Reasonable Number of Dispensaries 4/5 – Does Not Require Vertical Integration 0/2 – Ownership/Employment Restrictions 0/2 – Provisions for Labor Standards 0/2 – Environmental Impact Regulations 0/2 – Choice of Dispensary Without Restrictions 2/2 Noncommercial Cultivation 0/20 – Personal Cultivation 0/15 – Collective Gardening 0/5 Explicit Right to Edibles/Concentrates/Other Forms 6/10 Does not Impose Bans or Limits on THC 2/10 Does not Impose Bans on CBD 5/10 Local Bans/Zoning 7/10
Ease of Navigation	66/100
Comprehensive Qualifying Conditions 37/50 Adding New Conditions 0/10 – Law/Regulations Allow for New Conditions 0/5 – System Works for Adding New Conditions 0/5 Reasonable Access for Minors 8/10 Reasonable Caregiver Background Checks 4/4 Number of Caregivers 1/2 Patient/ Practitioner- Focused Task Force or Advisory Board 0/2 Reasonable Fees (Patients and Caregivers) 10/10 Allows Multiple-Year Registrations 0/2 Reasonable Physician Requirements 2/5 Does Not Classify Cannabis as a Medicine of Last Resort 4/5
Functionality	55/100
Patients Able to Access Medicine at Dispensaries or by Cultivation 30/50 No Significant Administrative or Supply Problems 10/15 Patients Can Receive Legal Protections Within Reasonable Time Frame of Doctor's Recommendation 0/10 Reasonable Possession Limits 5/5 Reasonable Purchase Limits 5/5 Allows Patients to Medicate Where They Choose 3/5 Covered by Insurance/State Health Aid 0/3 Financial Hardship (Fee Waivers/Discount Medicine) 2/7
Consumer Safety and Provider Requirements	40.21/100
Dispensing 12.67/25 Staff Training 0/5 Standard Operating Procedures 3/5 – Facility Sanitary Conditions 0/1.25 – Storage Protocols 1/1.25 – Reasonable Security Protocols 1/1.25 – Inventory Control 1/1.25 Recall Protocol and Adverse Event Reporting 5/5 Product Labeling 2.67/5 – Product Contents, Including Source Material Identification 1.67/1.67 – Allergens 0/1.67 – Potency/Compound Identification 1/1.67 Required Testing 2/5 – Active Compound Identification 1/1.67 – Contaminants 0/1.67 – Potency 1/1.67 Grow/Cultivation 13.38/25 Staff Training 0/5 Standard Operating Procedures 2.13/5 – Facility and Equipment Sanitary Conditions 0/0.71 – Workforce Safety Protocols 0/0.71 – Storage Protocols (Short-Term and Long-Term Storage) 0.71/0.71 – Reasonable Security Protocols 0.71/0.71 – Batch and Lot Tracking 0.71/0.71 – Disposal/Waste 0/0.71 – Water Management 0/0.71 Pesticide Guidance 3/5 – Pesticide Guidance 2/2.5 – Pesticide Labeling 1/2.5 Required Testing 3.25/5 – Active Ingredient Identification 1.25/1.25 – Contaminants 1/1.25 – Potency 1/1.25 – Sample Retention 0/1.25 Recall Protocol and Adverse Event Reporting 5/5 Manufacturing 11.67/25 Staff Training 0/5 Standard Operating Procedures 2/5 – Facility and Equipment Sanitary Conditions 0/1 – Workforce Safety Protocols 0/1 – Storage Protocols 1/1 – Reasonable Security Protocols 0/1 – Batch and Lot Tracking 1/1 Product Labeling 2.67/5 – Product Contents, Including Source Material Identification 1.67/1.67 – Allergens 0/1.67 – Potency and Compound Information 1/1.67 Required Testing 2/5 – Active Ingredient Identification 1/1 – Contaminants 0/1 – Potency 1/1 – Shelf Life Testing 0/1 – Sample Retention 0/1 Recall Protocol and Adverse Event Reporting 5/5 Laboratory Operations 2.49/25 Staff Training 0/5 Method Validation in Accordance with AHP Guidelines 0/5 Result Reporting 0/5 Independent or Third Party 0/5 Standard Operating Procedures and Protocols 2.49/5 – Equipment and Instrument Calibration 0/0.83 – Sample Tracking 0.83/0.83 – Facility and Equipment Sanitary Conditions 0.83/0.83 – Disposal/Waste 0/0.83 – Storage Protocols 0.83/0.83 – Workforce Safety Protocols 0/0.83
Covid Response	13/20
Delivery Available? 6/6 Curbside Pickup Available? 0/2 Medical Cannabis Essential? 7/7 Telemedicine Available? 0/5
Excerpted from ASA's 2020 State of the States Report.

Becoming a Patient in Texas

Recommending Cannabis in Texas

History of Medical Cannabis in Texas

Policy Recommendations Texas